INDIGO: Obexelimab Cut IgG4-RD Flares — No Kidney-Specific Endpoints Reported
In the phase 3 INDIGO trial, weekly subcutaneous obexelimab reduced rescue-requiring flares and glucocorticoid rescue exposure versus placebo in active IgG4-related disease. The primary NEJM report does not include kidney-specific efficacy endpoints.